Connect with us

Emerging Markets

Rjd Green Inc (OTCMKTS: RJDG) Record Revenue Growth & Profits and an Aggressive Acquisition Strategy in Medical Billing (IOSoft, Silex Holdings & Earthlinc Environmental)

Published

12 months ago

on

Rjd Green Inc (OTCMKTS: RJDG) is making an explosive move up the charts in recent trading while the overall markets see deep declines. On Tuesday alone RJDG was up 55% and trading $500,000 in dollar volume as it rockets up into copper land after reversing off established support levels of $0.0045. On Wednesday RJDG was up over 30% in the first 20 minutes of trading. The stock is quickly getting noticed by investors; this Company is making money and profits are growing exponentially. Now management is focused on major acquisitions in 20222 targeting billing Companies that offer EBITDA of 20% -30% RJDG is looking to acquire companies with $5,000,000 – $20,000,000 in annual revenues.  This is a low float stock too; while authorized shares is 750 million, the OS is 359,357,992 which has not increased for over a year as the Company has little debt and is making money, RJDG reported $387,800 in net income in the past 6 months and recently projected 2022 revenues would be record $5 million plus. Currently there are just 104,823,459 in the public float worth $1,140,000. 

RJDG is a diamond in the rough; this is a pink sheet Company that is making money and they are quickly lowering their operating costs while increasing revenues. For the year end 2021 the Company reported $4.4 million in revenues and $411,000 in net income. The Company has a backlog for Silex Holdings over $1,000,000 as of February 28, 2022, and IO Soft Inc. has slowly increased service contracts from the additional software platforms launched in 2022, as well, additional business development contracts have been put in place.  The stock popped to $0.028 in early 2021, investors are looking for RJDG to break north of this and finally get noticed by the investment community and start seeing some real price movement.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Rjd Green Inc (OTCMKTS: RJDG) operates as a holding company with a focus of acquiring and managing assets and companies. The Company is led by visionary CEO Ron Brewer who started of as COO before stepping into the CEO role. Mr. Brewer has been extensively involved in public Company formation and M&A activities and has big plans for RJDG. Mr. Brewer has made it clear he has acquisition efforts in place and rapid expansion on deck. Mr. Brewer has served as Managing Director of Southbridge Advisory Group since 1995. Southbridge is a boutique management firm with a primary focus in management services and merger / acquisition representation. RJD Green operates in three divisions:  

RJD Green Healthcare Services Division, which owns IOSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers. 

Earthlinc Environmental Services Division, which provides green environmental services and technologies. Earthlinc Environmental Solutions was formed to bring forward green applied technologies and offer environmental services with a focus in North America, providing performance driven solutions for environmental based issues in both corporate and small business needs. RJD Green Healthcare Division has developed a business model that utilizes the healthcare industry experience and extensive industry relationships of RJDG’S management and team. 

Silex Holdings Division, which is focused in specialty construction and industrial services. The initial operations, Silex Interiors, fills a market niche between the Home Depots and local contractors. Silex manufactures and installs granite and other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and DIY customer. Silex Holdings Inc. was formed for the purpose of acquiring and managing high growth assets and business enterprise. Silex Holdings is focused on acquisitions in specialty niched industrial contracting, and building material products and services. 

To Find out the inside Scoop on RJDG Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RJDG

RJD Green is currently seeking merger & acquisition opportunities in companies or ventures that offer transparent organic growth capability with their market niche. The market niche can be well defined by competition, long-term stability of market, geographic size, market penetration capabilities, and team industry capabilities. RJDG seeks companies with $5,000,000 – $20,000,000 in annual revenues. RJD seasoned management team has a significant experience in launching emerging growth and restructuring of companies, therefore they will review opportunities that can offer the same said definitions previously mentioned while reflecting transparent capabilities of successfully reaching appropriate investment returns.  

In April RJDG announced highlights from the Quarterly Report for the six months ended February 28, 2022. For the Six Months ending February 28, 2022 RJDG had Revenue of $2,384,112 and EBITDA Profit of $387,800 (+16.3%) RJDG has monthly recurring revenues of $397,352 with $4,397,300 in assets, liabilities of $1,518,121 of which $968,160 is internal debt between two of RJD Green’s wholly-owned subsidiaries. Management is confident in RJDG ability to top $5m in revenues in 2022 as the second half of the year historically sales are much higher. What is impressive about RJDG revenues is the Company did $387,800 in net income in the past 6 months and according to their annual report they did $411,000 in fiscal 2021 ending August 31, OS while their revenues have increased a little bit, their operating costs have dropped dramatically so that net income is now almost double of what it was a year ago. This Company is making money, slowly increasing revenues while significantly cutting costs. In April RJD Green management said April revenues were $406,992 with Net Operating Profit of 14.9% and EBITDTA of 17.9%. Another record month in both revenues and net income. 

RJDG has a strong executive management team including Jerry Niblett COO a seasoned oil and gas executive whose management expertise includes executive management, operations management in the energy sector, as well as direct management. His corporate employment includes; Dominion Energy, Texaco, Shell and Sunoco Pipeline LP. Jerry helped structure an organizational growth from $37,000,000 EBITDA to $1,000,000,000 EBITDA in 8 years and had direct P/L responsibilities for annual expense budgets in excess of $25,000,000 and capital integration in excess of $500,000,000. 

John Rabbitt, the Company’s CFO has extensive and diverse background in business evolved through consistent promotion and growth within fortune 500 firms including The Pillsbury Company and PepsiCo, in addition to the CPA firm of Ernst and Ernst. Mr. Rabitt played a key role in assisting the growth of MEI Corporation from $20 million annual revenue to $850 million annual revenue in nine years, at which time it was acquired by PepsiCo. He also has served in CEO/COO and CFO positions for firms ranging from $5,000,000 to $300,000,000 annual revenue. He also served as a member of PepsiCo’s Mid-West Advisory Board, and as a Director and Secretary/Treasurer of their largest canning division. 

On may 18 RJDG announced their subsidiary, IOSoft Inc., received two additional corporate agreements for usage of services from the ioSoft Suites software platform. ioSoft Suites: where expedited payment systems are now teamed with claims processing and adjudication, a multi-level communications system, and accurate data collect software systems. IOSoft offers an integrated system pricing and payment of claims that enhances productivity, efficiency, and costs. The software solutions can be utilized individually or as a total claims and payment management system. 

ioSoft LinkUP©  is the ultimate communication interface that enables the plan participant to access their ID card, update enrollment and access their claim information 24/7 using their iPhone or Android. The Plan Administrator has 24/7 access through their tablet or laptop to review and approve enrollment or access the system data base as needed. 

RJDG subsidiary IOSoft provides proprietary software for medical billing, Healthcare claims adjudication, automotive warranty payments, and electronic payments between healthcare Payers and Providers, along with payment software platforms for corporations, government & institutional organizations. Since formation, IOSoft has been a third-party developer of software and provides IT support for the platforms developed. The primary focus of IOSoft is in healthcare payment systems where IOSoft can provide unique payment technologies and leading-edge claim services, and software that can be integrated with legacy or existing systems of healthcare payers and providers such as, major health insurance carriers and third-party administrators. IOSoft provides targeted product offerings for healthcare providers, provider networks, physicians and hospitals, and clearinghouse companies. 

Fore More on RJDG Subscribe Right Now!

Currently trading at a $3.9 million market valuation RJDG has been ignored by the investment community for too long; this Company is making money and revenues are increasing rapidly. But management is getting itchy and has made is clear they are looking to close major acquisition in 2022 in the medical billing space; they are specifically looking for Companies with $5,000,000 – $20,000,000 in annual revenues to acquire. RJDG is a low float stock with just 104,823,459 shares in the public float worth $1,140,000. On Tuesday alone the stock traded $500,000 in dollar volume and was up over 50% In the past revenues were stagnant and operating costs were high however management has been slowly growing revenues whole significantly reducing costs and is making more money now than they ever have. Management is clearly gearing up for something big, they have not diluted the stock since last August and are looking to close some major Acquisitions. Acquisitions news, especially in the $5,000,000 – $20,000,000 in annual revenues level could be the vehicle that really puts a fire under RJDG and it goes into a whole new dimension. The stock is significantly undervalued, but in the past, it has bored investors. That could all be changing now. Microcapdaily will be covering RJDG as the Reverse merger unfolds so make sure you subscribe to Microcapdaily right now so you don’t miss it. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in RJDG either long or short and we have not been compensated for this article.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

3 days ago

on

May 31, 2023

By

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

2 weeks ago

on

May 21, 2023

By

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Emerging Markets

GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing

Published

3 weeks ago

on

May 14, 2023

By

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12.

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12. This represents an impressive 137% increase; the volume has been off the hook. If you look at their historical chart, $GSIT had meager volume, sometimes as low as 300 shares traded in a day. If you do the math, that’s less than $500 worth of shares traded in a day – safe to say it was virtually illiquid.

So what happened, and what drove the stock to trade 50M shares with filings or news releases?

After an in-depth examination, GSI Technology, Inc. appears to have experienced a notable turning point in its market trajectory. The catalyst for this transformation was the company’s prominent feature on Fox News, triggering an exponential dissemination of information across various platforms. It is worth highlighting an intriguing phenomenon that tends to transpire in such circumstances: purchasing shares often induces a ripple effect, encouraging further buying activity.

With Fox News bringing the company into the spotlight and stimulating investor interest, a domino effect occurred among astute day traders who eagerly seized the opportunity to partake in this promising venture. Consequently, the trading volume for GSI Technology, Inc. skyrocketed to unprecedented levels, surpassing all previously recorded thresholds.

This surge in volume stands as a testament to the immense enthusiasm that enveloped the market as traders recognized the tremendous potential inherent in $GSIT. This collective enthusiasm resulted in an extraordinary demonstration of market engagement, reflecting a widespread acknowledgment of the company’s significance and the opportunities it presents.

https://twitter.com/SamanthaLaDuc/status/1657033207412293634?s=20

This development showcases the power of influential media coverage and underscores the intriguing dynamics that can arise when investor sentiment aligns with a compelling market narrative.

To Discover the Inside Scoop on GSIT, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Founded in 1995, GSI Technology Inc. has established itself as a prominent provider of semiconductor memory solutions. The company is focused on introducing new products that capitalize on its core strengths, which include radiation-hardened memory products for extreme environments and Gemini, an advanced processing unit (APU) designed to enhance performance in various artificial intelligence (AI) applications. Headquartered in Sunnyvale, California, GSI Technology operates sales offices in the Americas, Europe, and Asia.

GSI Technology is on the verge of reporting its earnings next week, and the company operates in the storage business, which supports the development of highly efficient AI chips. Traditionally, computing involves separate chips for storage and computation, necessitating frequent data exchange. This process incurs significant power consumption and presents scalability challenges.

To address these limitations, GSI Technology has developed a groundbreaking solution called In-memory processing. This innovation substantially reduces computation time from minutes to seconds, milliseconds, or even microseconds. Notably, it also significantly diminishes power consumption and overall cost of ownership. The key to this improvement lies in the massive parallel data processing offered by GSI’s technology, featuring two million-bit processors per chip compared to thousands found in standard graphic processing units (GPUs). Consequently, the system becomes more scalable, enabling efficient and accelerated AI processing.

By streamlining the computing process and integrating storage and computation on a single chip, GSI Technology aims to revolutionize AI processing. This approach offers notable benefits regarding power efficiency, computational speed, and scalability, making it an attractive solution for a wide range of AI applications.

In conclusion, GSI Technology, Inc. is poised to deliver innovative semiconductor memory solutions emphasizing AI chip development. The company aims to reduce computation time, power consumption, and total ownership cost through its In-memory processing technology while significantly improving scalability. With its upcoming earnings report, investors and industry observers will closely watch the company’s progress in the storage business and AI chip development.

We will update you on GSIT when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with GSIT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.